Back to News
Market Impact: 0.15
Alpha Tau Completes Enrollment In IMPACT Pancreatic Cancer Study Of Alpha DaRT
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsCorporate Guidance & Outlook
Alpha Tau Medical (DRTS) said patient enrollment is complete for its multicenter IMPACT pilot study testing Alpha DaRT plus first-line chemotherapy in newly diagnosed, unresectable locally advanced or metastatic pancreatic cancer. The update removes an operational trial milestone, but no efficacy/safety results were provided. Overall, it is a modest positive catalyst likely to have limited near-term price impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.12
Ticker Sentiment
DRTS0.25
More News
- The IPO drought is driving private equity-owned companies to the debt market to pay investors
- CoreWeave credit default swaps hit distress levels as investors sour on AI debt
- FDA approves Enspryng for thyroid eye disease treatment
- Giant Taiwanese chipmaker TSMC confirms it’s in talks with Elon Musk to join ‘Terafab’ complex in Texas: ‘The AI market continues to be very strong’
- The Tesla Roadster 2 Is Here—and It Flies
- Hybe shares jump 10% as K-pop sensation BTS' tour lifts earnings hopes